Durvalumab (IMFINZI®) combined with transarterial chemoembolization (TACE) and bevacizumab lowered the chance of liver cancer progression or death by 23%.

At the 2024 ASCO GI Cancers Symposium, Coherus showcased encouraging Phase 2 trial results for Casdozokitug, an innovative IL-27-targeted antibody.

Argo Biopharma unveiled exclusive RNAi therapy licensing deals with Novartis Pharma.

AEON Biopharma Shares Positive Data on ABP-450 Treatment for Cervical Dystonia and PTSD at Neurotoxin Conference.

Vor Bio Commences Treatment on Initial Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Shares Company Progress Update.

Evommune Reveals Launch of an Early-Stage Study for Its Novel MRGPRX2 Inhibitor Aimed at Managing Persistent Idiopathic Hives.

PeproMene Bio Announces First Patient in Cohort 1 Achieves Complete Remission in B-ALL Phase 1 Trial with PMB-CT01 at City of Hope.

Immunity Pharma, a clinical-stage neurology specialist, announced positive initial results from its Phase 2a IPL344 trial in ALS patients.

Kairos Pharma, Ltd., specializing in developing new cancer treatments, has started a Phase 1 trial of its leading combination therapy. The study tests their drug ENV105 with osimertinib against non-small cell lung cancer.

Adagene Inc., a leader in antibody therapeutics, shared research at the 2024 ASCO Symposium on Gastrointestinal Cancers in San Francisco.

Regenxbio announces phase II aaviate ® The interim data of the trial were positive. Abbv-rgx-314 administered through sclera was used to treat wet AMD.

Calypso Biotech to be acquired by Novartis under a deal with a $250M upfront and potential $175M in milestones, with their lead antibody, CALY-002, targeting IL-15.